Nerandomilast

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

About Nerandomilast

Nerandomilast is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2025. DrugCentral lists 5 molecular targets, including PDE4B, PDE7A and PDE4D. Recorded indications include Idiopathic pulmonary fibrosis.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Idiopathic pulmonary fibrosis

Mechanism & targets

Molecular targets (5)

Target	Gene	Action	Activity
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	PDE4B	inhibitor	IC50 7.99
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A	PDE7A	inhibitor	IC50 7.86
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	PDE4D	inhibitor	IC50 7.04
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	PDE3A	inhibitor	IC50 6.92
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	PDE4A	inhibitor	IC50 6.61

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2025-10-07	FDA	—	Boehringer Ingelheim	Yes

ATC classification

ATC code	Therapeutic hierarchy
L04AA61	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nerandomilast is on its molecule page.

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: UHYCLWAANUGUMN-SSEXGKCCSA-N
• PubChem CID: 166177189

C1CC(C1)(CO)NC2=NC(=NC3=C2[S@](=O)CC3)N4CCC(CC4)C5=NC=C(C=N5)Cl

Sources & how this page is made

This page is compiled automatically from public scientific databases and is refreshed when those sources are re-ingested. It is not written or reviewed by a clinician.

• DrugCentral — structures, indications, targets, approvals (CC BY-SA 4.0)
• FDA Orange Book — patents and exclusivity
• FDA Adverse Event Reporting System (FAERS) — adverse-event signals
• PharmGKB / CPIC — pharmacogenomics
• PubChem — chemical identifiers